Vnitr Lek 2024, 70(3):E10-E12 | DOI: 10.36290/vnl.2024.041

Biological therapy of interstitial lung diseases

Martina Šterclová
Pneumologická klinika 2. LF UK a FN Motol, Pneumologická klinika 1. LF UK a FTN, Praha

Biological therapies, despite their widespread use in other areas of pneumology, are not typically the first-line treatment for patients with interstitial lung diseases. This is due to the relatively rare occurrence of these diseases and their incompletely understood etiopathogenesis. Biologics are most commonly used in patients with interstitial lung involvement in systemic connective tissue diseases; conversely, they do not have a routine place in the treatment of patients with idiopathic interstitial pneumonias. In patients with sarcoidosis, biological therapy constitutes third-line treatment. Before initiating biological treatment, it is necessary to consider its risks and thoroughly evaluate the patient, particularly regarding the risk of reactivation of certain infections.

Keywords: biological therapy, interstitial lung processes, idiopathic pulmonary fibrosis, sarcoidosis, connective tissue diseases.

Accepted: April 29, 2024; Published: May 6, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Šterclová M. Biological therapy of interstitial lung diseases. Vnitr Lek. 2024;70(3):E10-12. doi: 10.36290/vnl.2024.041.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Plichta J, Kuna P, Panek M. Biologic drugs in the treatment of chronic inflammatory pulmonary diseases: recent developments and future perspectives. Front Immunol 2023;14:1207641. Go to original source... Go to PubMed...
    2. Karampitsakos T, Vraka A, Bouros D, et al. Biologic Treatments in Interstitial Lung Diseases. Front Med (Lausanne) 2019;6:41. Go to original source... Go to PubMed...
    3. Harrington R, Harkins P, Conway R. Targeted Therapy in Rheumatoid-Arthritis-Related Interstitial Lung Disease. J Clin Med 2023;12(20):6657. Go to original source... Go to PubMed...
    4. Mendoza FA, Allawh T, Jimenez SA. Pharmacological treatment of systemic sclerosis-associated interstitial lung disease: an updated review and current approach to patient care. Clin Exp Rheumatol 2023;41(8):1704-1712. Go to original source... Go to PubMed...
    5. Khanna D, Lin CJF, Furst DE, Wagner B, Zucchetto M, Raghu G, Martinez FJ, Goldin J, Siegel J, Denton CP. Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis-Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial. Am J Respir Crit Care Med 2022;205(6):674-684. Go to original source... Go to PubMed...
    6. Kamenova A, Tzouvelekis A, Margaritopoulos GA. Recent advances in the treatment of systemic sclerosis associated interstitial lung disease. Front Med (Lausanne) 2023;10:1155771. Go to original source... Go to PubMed...
    7. Xu L, Wang F, Luo F. Rituximab for the treatment of connective tissue disease-associated interstitial lung disease: A systematic review and meta-analysis. Front Pharmacol 2022;13:1019915. Go to original source... Go to PubMed...
    8. Hallowell RW, Danoff SK. Diagnosis and Management of Myositis-Associated Lung Disease. Chest 2023;163(6):1476-1491. Go to original source... Go to PubMed...
    9. Baughman RP, Valeyre D, Korsten P, et al. ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir J 2021;58(6):2004079. Go to original source... Go to PubMed...
    10. Vorselaars ADM, Culver DA. Hit-hard and early versus step-up treatment in severe sarcoidosis. Curr Opin Pulm Med 2022;28(5):461-467. Go to original source... Go to PubMed...
    11. Borie R, Crestani B, Guyard A, Lidove O. Interstitial lung disease in lysosomal storage disorders. Eur Respir Rev 2021;30(160):200363. Go to original source... Go to PubMed...
    12. Trapnell BC, Inoue Y, Bonella F, et al. IMPALA Trial Investigators. Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis. N Engl J Med 2020;383(17):1635-1644. Go to original source... Go to PubMed...
    13. Bonella F, Manali ED, Papiris SA. Will inhalational GM-CSF replace whole lung lavage as a treatment for autoimmune pulmonary alveolar proteinosis? Many pole positions, not yet the final winner. Eur Respir J 2024;63:2301982 Go to original source... Go to PubMed...
    14. Asano K, Suzuki Y, Tanaka J, et al. Treatments of refractory eosinophilic lung diseases with biologics. Allergol Int 2023;72(1):31-40. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.